Senseonics (NYSE:SENS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Stock Performance

Senseonics stock opened at $0.59 on Thursday. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. The firm has a market cap of $352.55 million, a P/E ratio of -4.56 and a beta of 0.77. Senseonics has a 1-year low of $0.25 and a 1-year high of $0.75. The firm has a 50-day moving average of $0.36 and a 200-day moving average of $0.38.

Insiders Place Their Bets

In other news, CFO Frederick T. Sullivan purchased 124,933 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the transaction, the chief financial officer now directly owns 2,478,844 shares of the company’s stock, valued at $941,960.72. This trade represents a 5.31 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Timothy T. Goodnow purchased 315,000 shares of Senseonics stock in a transaction that occurred on Tuesday, December 10th. The stock was purchased at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the purchase, the chief executive officer now owns 11,310,355 shares of the company’s stock, valued at $3,506,210.05. This trade represents a 2.86 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Senseonics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in shares of Senseonics by 3.2% during the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after purchasing an additional 179,103 shares in the last quarter. Symmetry Partners LLC purchased a new stake in shares of Senseonics in the 3rd quarter worth approximately $164,000. Cubist Systematic Strategies LLC increased its position in Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after buying an additional 85,501 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Senseonics during the third quarter valued at $117,000. Finally, FMR LLC boosted its holdings in Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after acquiring an additional 167,970 shares in the last quarter. Hedge funds and other institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.